Zymeworks (NASDAQ:ZYME) Upgraded at Zacks Research

Zacks Research upgraded shares of Zymeworks (NASDAQ:ZYME) from a hold rating to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. B. Riley upgraded shares of Zymeworks to a “strong-buy” rating in a research report on Thursday, October 9th. HC Wainwright upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Wells Fargo & Company raised Zymeworks to a “hold” rating in a research note on Friday, October 24th. Wall Street Zen cut Zymeworks from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Zymeworks Trading Down 1.3%

NASDAQ ZYME opened at $19.12 on Tuesday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $19.98. The business’s 50 day moving average price is $16.57. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -19.71 and a beta of 1.51.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.The business had revenue of $4.40 million during the quarter.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.